Plasma and platelet excitatory amino acids in psychiatric disorders.
about
Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disordersNeurochemistry of the nucleus accumbens and its relevance to depression and antidepressant action in rodentsA Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical CorrelatesReview of pharmacological treatment in mood disorders and future directions for drug development.Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to dateA brief history of the development of antidepressant drugs: from monoamines to glutamateBiomarkers in schizophrenia: A focus on blood based diagnostics and theranosticsInflammatory biomarkers and depressionLong-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of miceClinical studies implementing glutamate neurotransmission in mood disorders.Delineation of molecular pathway activities of the chronic antidepressant treatment response suggests important roles for glutamatergic and ubiquitin-proteasome systemsReduced Mismatch Negativity is Associated with Increased Plasma Level of Glutamate in First-episode PsychosisAltered KYN/TRP, Gln/Glu, and Met/methionine sulfoxide ratios in the blood plasma of medication-free patients with major depressive disorderElevated levels of the NR2C subunit of the NMDA receptor in the locus coeruleus in depressionLow nNOS protein in the locus coeruleus in major depressionMagnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disordersBrain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis.Activation of the mGlu7 receptor elicits antidepressant-like effects in mice.Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatmentReduced cerebrospinal fluid ethanolamine concentration in major depressive disorder.Ketamine and the next generation of antidepressants with a rapid onset of actionMetabolomic identification of biochemical changes induced by fluoxetine and imipramine in a chronic mild stress mouse model of depression.Proteomic enrichment analysis of psychotic and affective disorders reveals common signatures in presynaptic glutamatergic signaling and energy metabolismEnhancing synaptic plasticity and cellular resilience to develop novel, improved treatments for mood disorders.Cellular and molecular mechanisms in the long-term action of antidepressantsRegulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system.Genetic ablation of the GluK4 kainate receptor subunit causes anxiolytic and antidepressant-like behavior in mice.Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders.Bcl-2 rs956572 polymorphism is associated with increased anterior cingulate cortical glutamate in euthymic bipolar I disorder.Are compounds acting at metabotropic glutamate receptors the answer to treating depression?The As and Ds of stress: metabolic, morphological and behavioral consequences.Impact of plasma transaminase levels on the peripheral blood glutamate levels and memory functions in healthy subjects.The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression.Reduced metabotropic glutamate receptor 5 in the Flinders Sensitive Line of rats, an animal model of depression: an autoradiographic study.The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects.Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression.Targeting the glutamatergic system to develop novel, improved therapeutics for mood disordersA psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders.The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.Depression and antidepressants: molecular and cellular aspects.
P2860
Q24632936-55CDB8E2-4F67-47AF-A8A5-CAC314279351Q24656267-A9ED8334-A094-4511-A179-DB8112508246Q26786354-8EC614E9-2F36-4AB6-B848-E16ABF55EA0CQ26853509-0DABF80D-3AF8-4BC8-8DC7-FAD1C239D6EBQ27004490-BBB608AC-3A1E-40E4-8F94-CFBC139E786AQ27028050-517F732F-66C8-474E-A66B-1AF70B27E665Q28068871-C0995FA2-82D0-46B2-AA66-C796E808868AQ28288750-C7EDBC6C-DBD3-4B30-BF6B-D3FC4E53AAB8Q28485938-E4C0508A-5E1C-425C-9164-359278298EC2Q30886466-60DE2CEC-83DD-43DE-9FDF-526484DBE84AQ33635613-4DE515BE-6A94-45FC-ACF9-8A8BDFA932A4Q33720060-8DC24D99-F2FF-4F1F-9A79-73444EBAEBDBQ33884852-653FB904-E796-4C73-8D84-9FDFAB5EB496Q34065490-D025B344-D618-4467-8548-5605D39B278FQ34071706-17CB1EB0-1194-4392-AB3D-F96829D3D5DEQ34204211-477CC06E-04A0-48CB-A2DB-5B3273058FA6Q34352492-31012628-29E8-4308-B6EB-498C7D3973FDQ34648343-2AC43690-9CF6-4A3A-B230-A90A015006E7Q34661625-48F08984-D0E8-4208-ADA9-50A84C7A1F34Q34965754-8FF73938-3474-474F-8630-2BC47D48B765Q34978041-3CBA4416-3BDC-4480-A4E8-EC50256387B7Q35157192-26F69405-62CA-4DBC-9BAB-38D87038E8C5Q35203647-3EAFC8A1-867B-4230-A4F1-AFAD9A3F6F85Q35236446-B5FEAA8B-4D18-49FF-A53E-E0767E3DEAAFQ35237067-7BB68559-B44B-401C-8F94-1A9D9A1CE3D4Q35611041-8426CA3E-E3DC-4E94-908D-64C6C4CBBF89Q35713544-2A3A95AA-FC7F-433D-AF31-368AF2A424DDQ36532151-1EC6295F-C1C9-4D12-AEED-2067F573685CQ36540042-866CEF4F-981A-42FF-9BC7-85E05EABC3D2Q36654331-4A3561A5-5B89-482E-B1ED-1927749D2296Q36710935-6495467A-E3CF-4013-A9EF-B7A951B5D5F4Q36713848-4A855B24-2B49-4962-B4A0-BBB40182E57AQ36800963-24EC730D-1E61-442E-8971-F9B18D5FE2A1Q36808854-C3A1A7E6-FFC8-4D1F-85FC-C6B3F5D4AC5CQ37067679-65FED149-6401-4E81-B220-C49D572128F5Q37104018-371B789C-EADF-4332-96E7-D8AD864B895EQ37143117-C7CD1EE1-0132-4C4B-8E61-8F8939DDAFAAQ37179033-D33ADC93-6BE1-453B-9EEB-E95E9E3F6DF6Q37387700-8EB9A1B8-9123-407B-8120-0A6D99FAAF2CQ37517285-A4723A58-D2F1-49A8-BC2C-4266652F039E
P2860
Plasma and platelet excitatory amino acids in psychiatric disorders.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh-hant
name
Plasma and platelet excitatory amino acids in psychiatric disorders.
@en
Plasma and platelet excitatory amino acids in psychiatric disorders.
@nl
type
label
Plasma and platelet excitatory amino acids in psychiatric disorders.
@en
Plasma and platelet excitatory amino acids in psychiatric disorders.
@nl
prefLabel
Plasma and platelet excitatory amino acids in psychiatric disorders.
@en
Plasma and platelet excitatory amino acids in psychiatric disorders.
@nl
P2093
P356
P1476
Plasma and platelet excitatory amino acids in psychiatric disorders.
@en
P2093
P304
P356
10.1176/AJP.150.11.1731
P407
P577
1993-11-01T00:00:00Z